Breaking News Instant updates and real-time market news.

SONS

Sonus

$7.57

-0.11 (-1.43%)

, VZ

Verizon

$48.35

-0.51 (-1.04%)

07:46
10/13/17
10/13
07:46
10/13/17
07:46

Sonus: Verizon contributed about 16% of revenue in Q3, AT&T about 11%

The company had two customers that contributed 10% or more of total revenue in the third quarter of 2017: Verizon (VZ), which contributed approximately 16% of revenue, and AT&T (T), which contributed approximately 11% of revenue.

SONS

Sonus

$7.57

-0.11 (-1.43%)

VZ

Verizon

$48.35

-0.51 (-1.04%)

T

AT&T

$35.86

-2.33 (-6.10%)

  • 19

    Oct

  • 24

    Oct

  • 30

    Oct

  • 30

    Oct

  • 01

    Nov

  • 29

    Nov

SONS Sonus
$7.57

-0.11 (-1.43%)

02/16/17
DADA
02/16/17
DOWNGRADE
Target $6.5
DADA
Neutral
Sonus downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst Mark Kelleher downgraded Sonus Networks to Neutral citing the "weak" service provider spending environment over the next few quarters as well as the company's dependence on a large customer in the second half of the year. The analyst cut his price target for the shares to $6.50 from $8 following the company's Q4 results.
06/01/17
WBLR
06/01/17
UPGRADE
WBLR
Outperform
Sonus upgraded to Outperform from Market Perform at William Blair
William Blair analyst Dmitry Netis upgraded Sonus Networks to Outperform after traveling with management. The analyst views the shares as oversold and thinks the Genband merger is being underappreciated by investors. He sees a "highly asymmetric risk/reward equation" from the merger. Netis' bull case has fair value of the combined entity at $13.35, implying 98% upside.
08/07/17
DADA
08/07/17
UPGRADE
Target $8.5
DADA
Buy
Sonus upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Mark Kelleher upgraded Sonus to Buy with an $8.50 price target following the better than expected Q2 report. The analyst believes modest revenue growth over the next several years will be driven by continued voice-over IP adoption, increased focus on security threats targeting real-time communications, and the move towards network functionality virtualization and earnings growth to accelerate from increased operational efficiency.
VZ Verizon
$48.35

-0.51 (-1.04%)

08/14/17
UBSW
08/14/17
NO CHANGE
Target $450
UBSW
Buy
Charter price target raised to $450 from $380 at UBS
UBS analyst John Hodulik raised his price target on Charter to $450 from $380 following his review of potential strategic options for the company. The analyst looked at the increasing M&A speculation and said many of the options come with significantly higher leverage than its current ratio. He believes it can be increased and supported with free cash flow while maintaining its investment grade rating. Hodulik said applying a conservative multiple would suggest significant upside to the shares setting a possible floor for a suitor. Hodulik reiterated his Buy rating on Charter shares.
09/05/17
MSCO
09/05/17
NO CHANGE
Target $53
MSCO
Overweight
Morgan Stanley predicts another 5c dividend hike coming for Verizon
Morgan Stanley analyst Simon Flannery said he sees a few arguments for Verizon continuing its recent dividend growth pattern, but he also sees some counter-arguments for a smaller increase or even a dividend freeze. In the end, he expects the company, which has raised its dividend annually since 2007, will hike its annual dividend by 5c this quarter, most likely with an announcement being made this Thursday, September 7. Flannery keeps an Overweight rating and $53 price target on Verizon shares.
09/20/17
DBAB
09/20/17
NO CHANGE
DBAB
Sprint, T-Mobile merger unlikely to get regulatory approval, says Deutsche Bank
Deutsche Bank analyst Matthew Niknam continues to believe a potential merger between Sprint (S) and T-Mobile (TMUS) faces "significant hurdles" and is ultimately unlikely to get past regulatory concerns. Merits of the deal, however, are "unparalleled, and very tough to debate," Niknam tells investors in a research note following CNBC's report of progressing deal talks. He believes derivative stock reactions on the news, namely strength in AT&T (T) and Verizon (VZ) and weakness in the tower names, could be at risk of reversing. Among the towers, the analyst has Buy ratings on American Tower (AMT) and Crown Castle (CCI).
09/20/17
OPCO
09/20/17
NO CHANGE
OPCO
Perform
Oppenheimer expects Sprint, T-Mobile merger to happen
Oppenheimer analyst Timothy Horan expect T-Mobile (TMUS) to merge with Sprint (S) in a stock-for-stock transaction at a $10 per share Sprint valuation. A T-Mobile/Sprint will be a better competitor to Verizon (VZ)/AT&T (T), the analyst says, adding that while the process is likely to have a few bumps and require time, he expects a merger to happen. Horan reiterates a Perform rating on Sprint's shares.
T AT&T
$35.86

-2.33 (-6.10%)

09/27/17
JPMS
09/27/17
NO CHANGE
JPMS
Overweight
TiVo extension with AT&T shows strength of portfolio, says JPMorgan
JPMorgan analyst Sterling Auty believes TiVo's (TIVO) intellectual property license deal extension with AT&T (T) to 2025 demonstrates the strength of its patent portfolio and its usefulness to the pay-TV providers. The deal also shows the longevity of the value of TiVo's IP portfolio, Auty tells investors in a research note. He keeps an Overweight rating on the shares.
09/28/17
RAJA
09/28/17
NO CHANGE
RAJA
DOJ appointment catalyst for CenturyLink, Level 3 deal, says Raymond James
Makan Delrahim was finally confirmed by the Senate yesterday as head of the Department of Justice Antitrust Division, Raymond James analyst Frank Louthan tells investors in a research note. He believes not having an antitrust head is at least partially to blame for the delay in mergers and acquisitions in the Technology & Communications space this year, including outstanding transactions like CenturyLink (CTL)/Level 3 Communications (LVLT) and AT&T (T)/Time Warner (TWX), as well as potential deals like Sprint (S)/T-Mobile U.S. (TMUS). The appointment of Delrahim is a catalyst for the approval of CenturyLink's acquisition of Level 3, where the Department of Justice has been the bottleneck, Louthan writes.

TODAY'S FREE FLY STORIES

TGT

Target

$62.92

1.16 (1.88%)

, GOOG

Alphabet

$988.20

3.75 (0.38%)

11:20
10/23/17
10/23
11:20
10/23/17
11:20
Hot Stocks
Target climbs as retailer gears up for crucial holiday season »

EXCLUSIVE BRANDS: After…

TGT

Target

$62.92

1.16 (1.88%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

WMT

Wal-Mart

$88.24

0.8 (0.91%)

AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 08

    Nov

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

  • 18

    Mar

XLF

Financial Select Sector

$26.67

0.025 (0.09%)

11:20
10/23/17
10/23
11:20
10/23/17
11:20
Options
Notable option play in SPDR Financial ETF Monday morning »

Notable option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:20
10/23/17
10/23
11:20
10/23/17
11:20
General news
Treasury announced a $45 B 4-week bill auction for Tuesday »

Treasury announced a $45…

$NSD

NASDAQ Market Internals

11:17
10/23/17
10/23
11:17
10/23/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
10/23/17
10/23
11:16
10/23/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$146.80

-2.81 (-1.88%)

11:15
10/23/17
10/23
11:15
10/23/17
11:15
Options
Palo Alto Networks put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

11:15
10/23/17
10/23
11:15
10/23/17
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:15
10/23/17
10/23
11:15
10/23/17
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

SINA

Sina

$110.48

-1.12 (-1.00%)

11:14
10/23/17
10/23
11:14
10/23/17
11:14
Hot Stocks
Aristeia says Glass Lewis endorses nominees for Sina board »

Aristeia Capital, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

JNJ

Johnson & Johnson

$143.95

1.5514 (1.09%)

11:13
10/23/17
10/23
11:13
10/23/17
11:13
Conference/Events
Johnson & Johnson management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

SNY

Sanofi

$49.59

0.075 (0.15%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$28.07

-0.15 (-0.53%)

11:11
10/23/17
10/23
11:11
10/23/17
11:11
Conference/Events
Worldwide Business Research to hold a summit »

BioNetwork Partnering…

SNY

Sanofi

$49.59

0.075 (0.15%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$28.07

-0.15 (-0.53%)

UNH

UnitedHealth

$207.31

-0.18 (-0.09%)

NVS

Novartis

$86.54

0.8 (0.93%)

HZNP

Horizon Pharma

$14.09

-0.05 (-0.35%)

ABBV

AbbVie

$95.55

-0.55 (-0.57%)

BAYRY

Bayer

$34.80

-0.41 (-1.16%)

MRK

Merck

$64.37

0.49 (0.77%)

RDHL

RedHill Biopharma

$9.25

0.47 (5.35%)

NBRV

Nabriva Therapeutics

$6.33

-0.31 (-4.67%)

PFE

Pfizer

$36.68

0.26 (0.71%)

TEVA

Teva

$14.70

-0.2 (-1.34%)

GILD

Gilead

$81.21

-0.38 (-0.47%)

ALXN

Alexion

$139.02

-1.44 (-1.03%)

GSK

GlaxoSmithKline

$40.76

-0.085 (-0.21%)

REGN

Regeneron

$432.98

-7.96 (-1.81%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

LLY

Eli Lilly

$87.85

0.62 (0.71%)

AMGN

Amgen

$182.96

-1.16 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

  • 27

    Oct

  • 28

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 08

    Nov

  • 09

    Nov

  • 13

    Nov

  • 16

    Nov

  • 16

    Nov

  • 30

    Nov

  • 30

    Nov

  • 02

    Dec

  • 04

    Dec

  • 02

    Feb

  • 03

    Feb

  • 12

    Feb

  • 30

    Apr

  • 17

    May

  • 28

    May

CUB

Cubic

$54.75

1.7 (3.20%)

11:10
10/23/17
10/23
11:10
10/23/17
11:10
Periodicals
MTA ready to roll out new payment system built by Cubic, NY Post reports »

The MTA is ready to roll…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:07
10/23/17
10/23
11:07
10/23/17
11:07
General news
4-Week Bill Announcement Offering Amount data reported »

4-Week Bill Announcement…

NTNX

Nutanix

$26.67

0.33 (1.25%)

11:05
10/23/17
10/23
11:05
10/23/17
11:05
Options
Nutanix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:05
10/23/17
10/23
11:05
10/23/17
11:05
General news
Euro$ interest rate futures are relatively steady »

Euro$ interest rate…

OPGN

OpGen

$0.37

-0.0014 (-0.38%)

11:01
10/23/17
10/23
11:01
10/23/17
11:01
Hot Stocks
OpGen announces award of $860K CDC contract »

OpGen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PETS

PetMed Express

$36.74

0.87 (2.43%)

11:00
10/23/17
10/23
11:00
10/23/17
11:00
Recommendations
PetMed Express analyst commentary  »

PetMed Express target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

EGO

Eldorado Gold

$1.79

-0.38 (-17.51%)

10:57
10/23/17
10/23
10:57
10/23/17
10:57
Downgrade
Eldorado Gold rating change  »

Eldorado Gold downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

TMUS

T-Mobile

$60.46

-1.05 (-1.71%)

, S

Sprint

$6.99

0.055 (0.79%)

10:55
10/23/17
10/23
10:55
10/23/17
10:55
Hot Stocks
T-Mobile adds 1.3M customers as Un-carrier remains mum on potential Sprint deal »

Shares of T-Mobile US…

TMUS

T-Mobile

$60.46

-1.05 (-1.71%)

S

Sprint

$6.99

0.055 (0.79%)

DTEGY

Deutsche Telekom

$18.06

-0.09 (-0.50%)

SFTBF

SoftBank

$88.50

1.25 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 16

    May

HAS

Hasbro

$98.19

1.52 (1.57%)

10:55
10/23/17
10/23
10:55
10/23/17
10:55
Options
Hasbro put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NWBI

Northwest Bancshares

$17.66

0.08 (0.46%)

10:52
10/23/17
10/23
10:52
10/23/17
10:52
Earnings
Northwest Bancshares reports Q3 EPS 24c, consensus 22c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FAT

Fat Brands

10:52
10/23/17
10/23
10:52
10/23/17
10:52
Syndicate
Fat Brands opens at $12.80, IPO priced at $12 per share »

TriPoint Global acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLX

Helix Energy

$6.85

-0.91 (-11.73%)

10:49
10/23/17
10/23
10:49
10/23/17
10:49
Hot Stocks
Helix Energy falls after saying strategic review concluded »

On Helix Energy's Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

DOVA

Dova Pharmaceuticals

$26.73

-0.4 (-1.47%)

10:46
10/23/17
10/23
10:46
10/23/17
10:46
Conference/Events
Dova Pharmaceuticals to hold a pharmaceutical update conference call »

Management, along with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
10/23/17
10/23
10:45
10/23/17
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.